IP Library Granted Patent US 12,290,700
Granted Patent B2
US 12,290,700 · App. 17/889,115 · Granted May 6, 2025

Adjustable illuminator for photodynamic therapy and diagnosis

Inventors: Thomas Boyajian (Wilmington, MA); Mark Carota (Chelmsford, MA); Brian Mazejka (Salem, NH)
Assignee: Sun Pharmaceutical Industries, Inc.
A61N5/062A61B5/0064A61B5/0082A61N2005/0626A61N2005/0633A61N2005/0642A61N2005/0651A61N2005/0652A61N2005/0662A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,700
App. No.
17/889,115
Granted
May 6, 2025
Kind
B2
Abstract

An adjustable illuminator for photodynamically diagnosing or treating a surface includes a plurality of first panels and at least one second panel. The plurality of first panels have wider widths and the at least one second panel has a narrower width. The narrower width is less than the wider widths. The illuminator further includes a plurality of light sources, each mounted to one of the plurality of first panels or the at least one second panel and configured to irradiate the surface with substantially uniform intensity visible light. The plurality of first panels and the at least one second panel are rotatably connected. The at least one second panel is connected on each side to one of the plurality of first panels. The second panel acts as a “lighted hinge” to reduce or eliminate optical dead spaces between adjacent panels when the illuminator is bent into a certain configuration.

Claims (27)

1. A method of photodynamically diagnosing or treating a patient, the method comprising:

applying 5-aminolevulinic acid (ALA) to a treatment surface on an extremity of the patient,

illuminating, by an illuminator comprising a plurality of light sources disposed on surfaces of a plurality of panels, the treatment surface of the patient;

wherein the plurality of panels are connected by hinged structures on inner side surfaces of adjacent panels, wherein the illuminator is configured to uniformly illuminate the treatment surface via the light sources;

positioning one of the plurality of panels as a center panel to face the treatment surface; and

positioning two or more of the plurality of panels to be extended from the center panel such that the plurality of panels are positioned to allow treatment of the extremities of the patient;

wherein each of the plurality of panels has two first edges and two second edges shorter than the two first edges, and the light sources are arranged such that a higher intensity of light is emitted proximate the second edges compared to the intensity of light emitted not proximate the second edges.

2. The method of claim 1 , wherein illuminating comprises outputting red light at a dose of about 30 J/cm 2 to about 150 J/cm 2 .

3. The method of claim 1 , wherein illuminating comprises outputting light at a variable irradiance density during treatment.

4. The method of claim 1 , wherein illuminating comprises outputting light at an irradiance density of 10 mW/cm 2 to 30 mW/cm 2 .

5. The method of claim 1 , wherein a plurality of the light sources are configured to emit light having a wavelength in a range of 400 nm to 700 nm.

6. The method of claim 1 , wherein illuminating comprises controlling illumination from each of the plurality of panels.

7. The method of claim 1 , wherein the treatment surface is located on the arms, legs or feet.

8. The method of claim 1 , wherein about 2 mg/cm 2 of ALA is applied to the treatment surface.

9. A system for photodynamically diagnosing or treating a patient, comprising:

an illuminator comprising five panels connected by hinged structures on inner side surfaces of adjacent panels;

light sources disposed on the five panels of the illuminator, the light sources being configured to uniformly illuminate a treatment surface of the patient, and

a controller and at least one sensor, the controller being configured to change intensities of the light sources of the illuminator with a controller in accordance with information received from the at least one sensor relating to a curvature of the treatment surface,

wherein each of the five panels has two first edges and two second edges shorter than the two first edges, and the light sources are arranged such that a higher intensity of light is emitted proximate the second edges compared to the intensity of light emitted not proximate the second edges, wherein each of the five panels is configured to allow selective control of illumination therefrom.

10. The system of claim 9 , wherein the light sources are configured to illuminate the treatment surface by outputting red light during at least part of the time when the treatment surface is illuminated.

11. The system of claim 9 , wherein the light sources are configured to illuminate the treatment surface by outputting blue light during at least part of the time when the treatment surface is illuminated.

12. The system of claim 9 , wherein:

the illuminator comprises at least three first panels having first widths, at least two second panels having second widths, wherein each of the second widths of the at least two second panels is narrower than each of the first widths of the at least three first panels; and

the at least three first panels and the at least two second panels are connected in an alternating manner such that each of the at least two second panels has a first lateral side connected to a respective one of the at least three first panels and a second lateral side connected to another respective one of the at least three first panels.

13. The system of claim 9 , wherein the sensor is configured to determine a size of the treatment surface of the patient.

14. The system of claim 13 , wherein the controller is configured to adjust an overall light dose based on the determined size of the treatment surface.

15. The system of claim 13 , further comprising at least one actuator configured to adjust positioning of panels based on the determined size of the treatment surface.

Assignments (2)
MERGER Recorded May 30, 2024
From: DUSA PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 067565/0986 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2024
From: BOYAJIAN, THOMAS; CAROTA, MARK; MAZEJKA, BRIAN
To: DUSA PHARMACEUTICALS, INC.
Reel/Frame 067553/0478 →
Continuity (4)
Continuation 16791004 · Feb 14, 2020
Division 15292731 · Oct 13, 2016
Provisional Application 62241902 · Oct 15, 2015
Related Publication 20220387816A1 · Dec 8, 2022
References Cited (400)
US 4100415A · Blaisdell et al. · 1978 [cited by applicant]
US 4344256A · King · 1982 [cited by applicant]
US 4667658A · Guibert · 1987 [cited by applicant]
US 4805202A · Deucher et al. · 1989 [cited by applicant]
US 4823858A · Perutz · 1989 [cited by applicant]
US 4832294A · Eidem · 1989 [cited by applicant]
US 5032400A · Wiersum et al. · 1991 [cited by applicant]
US 5079262A · Kennedy et al. · 1992 [cited by applicant]
US 5211938A · Kennedy et al. · 1993 [cited by applicant]
US 5441531A · Zarate et al. · 1995 [cited by applicant]
US 5474528A · Meserol · 1995 [cited by applicant]
US 5489279A · Meserol · 1996 [cited by applicant]
US 5505726A · Meserol · 1996 [cited by applicant]
US 5601838A · Hind · 1997 [cited by applicant]
US 5686065A · Haney · 1997 [cited by applicant]
US 5782895A · Zarate et al. · 1998 [cited by applicant]
US 5814008A · Chen et al. · 1998 [cited by applicant]
US 5849027A · Gart et al. · 1998 [cited by applicant]
US 5954703A · Golub · 1999 [cited by applicant]
US 6223071B1 · Lundahl et al. · 2001 [cited by applicant]
US 6231593B1 · Meserol · 2001 [cited by applicant]
US 6290713B1 · Russell · 2001 [cited by applicant]
US 6559183B1 · Schmid et al. · 2003 [cited by applicant]
US 6709446B2 · Lundahl et al. · 2004 [cited by applicant]
US 6897238B2 · Anderson · 2005 [cited by applicant]
US 6979101B2 · Sauska et al. · 2005 [cited by applicant]
US 7001413B2 · Butler · 2006 [cited by applicant]
US 7033381B1 · Larsen · 2006 [cited by applicant]
US 7131990B2 · Bansal et al. · 2006 [cited by applicant]
US 7156865B2 · Waldmann · 2007 [cited by applicant]
US 7190109B2 · Lundahl et al. · 2007 [cited by applicant]
US 7311722B2 · Larsen · 2007 [cited by applicant]
US 7347573B1 · Isler · 2008 [cited by applicant]
US 7723910B2 · Lundahl et al. · 2010 [cited by applicant]
US 7730893B2 · Dougal · 2010 [cited by applicant]
US 8030836B2 · Lundahl et al. · 2011 [cited by applicant]
US 8216289B2 · Lundahl et al. · 2012 [cited by applicant]
US 8226289B2 · Lindeberg · 2012 [cited by applicant]
US 8451601B2 · Bohn et al. · 2013 [cited by applicant]
US 8608737B2 · Mehta et al. · 2013 [cited by applicant]
US 8638546B2 · Hoshino · 2014 [cited by applicant]
US 8758418B2 · Lundahl et al. · 2014 [cited by applicant]
US 8759396B2 · Wulf et al. · 2014 [cited by applicant]
US 8899791B2 · Liu · 2014 [cited by applicant]
US 8947320B2 · King et al. · 2015 [cited by applicant]
US 9009984B2 · Caskey et al. · 2015 [cited by applicant]
US 9108045B2 · Sakamoto et al. · 2015 [cited by applicant]
US 9227082B2 · McDaniel · 2016 [cited by examiner]
US 9492681B2 · Aydt et al. · 2016 [cited by applicant]
US 9533170B2 · Dye et al. · 2017 [cited by applicant]
US 9597150B2 · Lundahl · 2017 [cited by applicant]
US 9723991B2 · Lundahl et al. · 2017 [cited by applicant]
US 10029116B2 · Lundahl · 2018 [cited by applicant]
US 10357567B1 · Lundahl et al. · 2019 [cited by applicant]
US 10589122B2 · Boyajian et al. · 2020 [cited by applicant]
US 10603508B2 · Boyajian et al. · 2020 [cited by applicant]
US 10688147B2 · Garruto et al. · 2020 [cited by applicant]
US 10786571B2 · Solioz et al. · 2020 [cited by applicant]
US 10814114B2 · Boyajian et al. · 2020 [cited by applicant]
US 11135293B2 · Lundahl et al. · 2021 [cited by applicant]
US 11179574B2 · Boyajian et al. · 2021 [cited by applicant]
US 11235169B1 · Osterloh et al. · 2022 [cited by applicant]
US 11333336B1 · Tobin et al. · 2022 [cited by applicant]
US 11446512B2 · Boyajian et al. · 2022 [cited by applicant]
US 11571478B2 · Lundahl et al. · 2023 [cited by applicant]
US 11697028B2 · Boyajian et al. · 2023 [cited by applicant]
US 20010021812A1 · Lundahl · 2001 [cited by examiner]
US 20020029071A1 · Whitehurst · 2002 [cited by applicant]
US 20030088296A1 · Waldmann · 2003 [cited by applicant]
US 20030216795A1 · Harth et al. · 2003 [cited by applicant]
US 20040010299A1 · Tolkoff et al. · 2004 [cited by applicant]
US 20040068305A1 · Bansal · 2004 [cited by examiner]
US 20040093043A1 · Edel et al. · 2004 [cited by applicant]
US 20040143308A1 · Lundahl et al. · 2004 [cited by applicant]
US 20040162596A1 · Altshuler et al. · 2004 [cited by applicant]
US 20040260365A1 · Groseth et al. · 2004 [cited by applicant]
US 20050075703A1 · Larsen · 2005 [cited by applicant]
US 20050090877A1 · Harth et al. · 2005 [cited by applicant]
US 20050093485A1 · Spivak · 2005 [cited by applicant]
US 20050157499A1 · Kim · 2005 [cited by applicant]
US 20060182790A1 · Mayoral · 2006 [cited by applicant]
US 20060241726A1 · Whitehurst · 2006 [cited by applicant]
US 20060253175A1 · Fan et al. · 2006 [cited by applicant]
US 20060274549A1 · Fukuyoshi · 2006 [cited by applicant]
US 20060287696A1 · Wright et al. · 2006 [cited by applicant]
US 20070021806A1 · Mercier et al. · 2007 [cited by applicant]
US 20070088410A1 · Chung et al. · 2007 [cited by applicant]
US 20070283655A1 · Tobin · 2007 [cited by applicant]
US 20080031924A1 · Gilson et al. · 2008 [cited by applicant]
US 20080180950A1 · Kang et al. · 2008 [cited by applicant]
US 20080188558A1 · Godal et al. · 2008 [cited by applicant]
US 20090099499A1 · Persin et al. · 2009 [cited by applicant]
US 20090177190A1 · Lee · 2009 [cited by applicant]
US 20090247932A1 · Barolet · 2009 [cited by applicant]
US 20090270946A1 · Spivak · 2009 [cited by applicant]
US 20090324727A1 · Foguet Roca · 2009 [cited by applicant]
US 20100010591A1 · Daffer · 2010 [cited by applicant]
US 20100118522A1 · Hente · 2010 [cited by applicant]
US 20100174222A1 · Mcdaniel · 2010 [cited by applicant]
US 20100174223A1 · Sakamoto et al. · 2010 [cited by applicant]
US 20100179469A1 · Hammond et al. · 2010 [cited by applicant]
US 20100298758A1 · Christiansen et al. · 2010 [cited by applicant]
US 20110020441A1 · Klaveness et al. · 2011 [cited by applicant]
US 20110053965A1 · Trigiante · 2011 [cited by applicant]
US 20110106222A1 · Wilson et al. · 2011 [cited by applicant]
US 20110218597A1 · Wang · 2011 [cited by applicant]
US 20110224598A1 · Barolet · 2011 [cited by applicant]
US 20110243789A1 · Roberts · 2011 [cited by applicant]
US 20110270092A1 · Kang et al. · 2011 [cited by applicant]
US 20110293528A1 · Godal et al. · 2011 [cited by applicant]
US 20120004711A1 · Hilty · 2012 [cited by applicant]
US 20120035719A1 · Forster et al. · 2012 [cited by applicant]
US 20120104277A1 · Morren · 2012 [cited by applicant]
US 20120129879A1 · Cantrell et al. · 2012 [cited by applicant]
US 20120283328A1 · Modi · 2012 [cited by applicant]
US 20120287671A1 · Parker et al. · 2012 [cited by applicant]
US 20120296260A1 · Vizethum et al. · 2012 [cited by applicant]
US 20120303101A1 · Rogers et al. · 2012 [cited by applicant]
US 20130066404A1 · Tapper et al. · 2013 [cited by applicant]
US 20130066405A1 · Dougal · 2013 [cited by applicant]
US 20130102906A1 · Lundahl et al. · 2013 [cited by applicant]
US 20130190845A1 · Liu et al. · 2013 [cited by applicant]
US 20130274834A1 · Barolet et al. · 2013 [cited by applicant]
US 20130289089A1 · Morris et al. · 2013 [cited by applicant]
US 20130304019A1 · Cooper et al. · 2013 [cited by applicant]
US 20130315999A1 · Paithankar et al. · 2013 [cited by applicant]
US 20140010761A1 · Parent et al. · 2014 [cited by applicant]
US 20140067024A1 · Jones et al. · 2014 [cited by applicant]
US 20140121631A1 · Bean et al. · 2014 [cited by applicant]
US 20140303547A1 · Loupis et al. · 2014 [cited by applicant]
US 20150018751A1 · Kerber · 2015 [cited by applicant]
US 20150021221A1 · Hendrickson et al. · 2015 [cited by applicant]
US 20150162109A1 · Nager · 2015 [cited by applicant]
US 20150190651A1 · Jayavanth et al. · 2015 [cited by applicant]
US 20150217132A1 · Makkapati et al. · 2015 [cited by applicant]
US 20150238776A1 · Sakamoto et al. · 2015 [cited by applicant]
US 20150290028A1 · Isserow et al. · 2015 [cited by applicant]
US 20150290470A1 · Tapper et al. · 2015 [cited by applicant]
US 20160008623A1 · Jones et al. · 2016 [cited by applicant]
US 20160030565A1 · Wulf et al. · 2016 [cited by applicant]
US 20160045015A1 · Baldwin · 2016 [cited by applicant]
US 20160045757A1 · Groseth · 2016 [cited by applicant]
US 20160051832A1 · Mordon · 2016 [cited by applicant]
US 20160166846A1 · Chae · 2016 [cited by applicant]
US 20160175608A1 · Livingston · 2016 [cited by applicant]
US 20160175609A1 · Dye et al. · 2016 [cited by applicant]
US 20160175610A1 · Livingston et al. · 2016 [cited by applicant]
US 20160255941A1 · Yang et al. · 2016 [cited by applicant]
US 20160346392A1 · Wulf · 2016 [cited by applicant]
US 20170106205A1 · Boyajian et al. · 2017 [cited by applicant]
US 20170216616A1 · Boyajian et al. · 2017 [cited by applicant]
US 20180043178A1 · Iguchi et al. · 2018 [cited by applicant]
US 20180178034A1 · Iguchi et al. · 2018 [cited by applicant]
US 20180311507A1 · Barolet · 2018 [cited by applicant]
US 20180344852A1 · Solioz et al. · 2018 [cited by applicant]
US 20190105261A1 · Waugh et al. · 2019 [cited by applicant]
US 20190216927A1 · Lundahl et al. · 2019 [cited by applicant]
US 20190290763A1 · Lundahl et al. · 2019 [cited by applicant]
US 20200100997A1 · Soler et al. · 2020 [cited by applicant]
US 20200261580A1 · Willey · 2020 [cited by applicant]
US 20200269063A1 · Boyajian et al. · 2020 [cited by applicant]
US 20200398071A1 · Boyajian et al. · 2020 [cited by applicant]
US 20220008538A1 · Lundahl et al. · 2022 [cited by applicant]
US 20220040494A1 · Boyajian et al. · 2022 [cited by applicant]
US 20220370610A1 · Lundahl et al. · 2022 [cited by applicant]
US 20220387816A1 · Boyajian et al. · 2022 [cited by applicant]
US 20230001227A1 · Boyajian et al. · 2023 [cited by applicant]
US 20230131170A1 · Sanghvi et al. · 2023 [cited by applicant]
US 20240335360A1 · Foguet et al. · 2024 [cited by applicant]
US 20240335380A1 · Foguet et al. · 2024 [cited by applicant]
AU 4386901A1 · 2001 [cited by applicant]
BR 1020140191941B1 · 2022 [cited by applicant]
CA 2706642C · 2002 [cited by applicant]
CA 2568744A1 · 2005 [cited by applicant]
CA 2738861A1 · 2011 [cited by applicant]
CN 1941799A · 2007 [cited by applicant]
CN 103043330A · 2013 [cited by applicant]
CN 203097540U · 2013 [cited by applicant]
CN 206822964U · 2018 [cited by applicant]
DE 69827286T2 · 2005 [cited by applicant]
EP 1162400A2 · 2001 [cited by applicant]
EP 1238652A1 · 2002 [cited by applicant]
EP 1311259B1 · 2003 [cited by applicant]
EP 2456382B1 · 2012 [cited by applicant]
EP 3143986A1 · 2017 [cited by applicant]
FR 2813747A · 2002 [cited by applicant]
JP S49002185 · 1974 [cited by applicant]
JP H04500770A · 1992 [cited by applicant]
JP 2524147B2 · 1996 [cited by applicant]
JP 2731032B · 1998 [cited by applicant]
JP 2736475B2 · 1998 [cited by applicant]
JP H11239624A · 1999 [cited by applicant]
JP 2000177155A · 2000 [cited by applicant]
JP 2002529495A · 2002 [cited by applicant]
JP 2006511275A · 2006 [cited by applicant]
JP 2006519047A · 2006 [cited by applicant]
JP 2009055969A · 2009 [cited by applicant]
JP 2010513363 · 2010 [cited by applicant]
JP 2010515714A · 2010 [cited by applicant]
JP 2010212819A · 2010 [cited by applicant]
JP 4855775B2 · 2012 [cited by applicant]
JP 2013019237A · 2013 [cited by applicant]
JP 2014067529A · 2014 [cited by applicant]
KR 20070063718A · 2007 [cited by applicant]
KR 20090005028A · 2009 [cited by applicant]
KR 20090055891A · 2009 [cited by applicant]
KR 101180416B1 · 2012 [cited by applicant]
KR 20120100861A · 2012 [cited by applicant]
KR 101237952B1 · 2013 [cited by applicant]
KR 101244434B1 · 2013 [cited by applicant]
KR 101576623B1 · 2015 [cited by applicant]
WO WO8707321A1 · 1987 [cited by applicant]
WO WO9309847A1 · 1993 [cited by applicant]
WO WO9507077A1 · 1993 [cited by applicant]
WO WO9606602A1 · 1996 [cited by applicant]
WO WO9715226A1 · 1997 [cited by applicant]
WO WO9922802A1 · 1999 [cited by applicant]
WO WO9956827 · 1999 [cited by applicant]
WO WO0041726A2 · 2000 [cited by applicant]
WO WO0213788A1 · 2002 [cited by applicant]
WO WO0230512A1 · 2002 [cited by applicant]
WO WO02062420A1 · 2002 [cited by applicant]
WO WO02098508A1 · 2002 [cited by applicant]
WO WO2005030328A2 · 2005 [cited by applicant]
WO WO2006013390A1 · 2006 [cited by applicant]
WO WO2007090256A1 · 2007 [cited by applicant]
WO WO2007112427A2 · 2007 [cited by applicant]
WO WO2009003173A1 · 2008 [cited by applicant]
WO WO2009074811A2 · 2009 [cited by applicant]
WO WO2009131727A2 · 2009 [cited by applicant]
WO WO2010044879A2 · 2010 [cited by applicant]
WO WO2010128751A2 · 2010 [cited by applicant]
WO WO2011084722A1 · 2011 [cited by applicant]
WO WO2011124912A1 · 2011 [cited by applicant]
WO WO2011153599A1 · 2011 [cited by applicant]
WO WO2012086991A2 · 2012 [cited by applicant]
WO WO2013110021A1 · 2013 [cited by applicant]
WO WO2014064075A1 · 2014 [cited by applicant]
WO WO2014131115A1 · 2014 [cited by applicant]
WO WO2014147624A1 · 2014 [cited by applicant]
WO WO2015041919A1 · 2015 [cited by applicant]
WO WO2017066270A1 · 2017 [cited by applicant]
WO WO2019018408A1 · 2019 [cited by applicant]
WO WO2024209064A1 · 2024 [cited by applicant]
WO WO2024209073A1 · 2024 [cited by applicant]
A Pharmacokinetic Study of Levulan Kerastick (aminolevulinic acid HCI) for Topical Solution, 20%, Under Maximal Use Conditions, Clinical Study Report, DUSA Pharmaceuticals, Jun. 10, 2015, 68 pages. [cited by applicant]
A Pharmacokinetic Study of Levulan Kerastick (aminolevulinic acid HCI) for Topical Solution, 20%, Under Maximal Use Conditions, Clinical Study Report, DUSA Pharmaceuticals, Jul. 19, 2016, 69 pages. [cited by applicant]
A Phase 2 Study of Photodynamic Therapy With Levulan Topical Solution—Blue Light Versus Levulan Topical Solution Vehicle—Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities, Clinical Study Report,… [cited by applicant]
A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution—Blue Light Versus Topical Solution Vehicle—Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities, Clinical Study Repor… [cited by applicant]
Complainant's Initial Statement Regarding the Public Interest, filed Jun. 25, 2024 in ITC Investigation No. 337-TA-1411. [cited by applicant]
Complaint filed Jun. 25, 2024 in [cited by applicant]
Complaint of Sun Pharmaceutical Industries, Inc. filed Jun. 25, 2024 in ITC Investigation No. 337-TA-1411. [cited by applicant]
Curriculum Vitae of Jose Sasian, Ph.D., filed Aug. 22, 2024 in IPR 2024-00874. [cited by applicant]
Declaration of Jose Sasian, Ph.D., filed Aug. 22, 2024 in IPR 2024-00874. [cited by applicant]
Declaration of Eric Bretschneider, Ph.D., filed Apr. 30, 2024 in IPR 2024-00874. [cited by applicant]
Declaration of Michael Ehrenreich, M.D., for filed Aug. 21, 2024 in IPR of 2024-01312. [cited by applicant]
Declaration of Robert E. Grove, Ph.D., filed Aug. 21, 2024 in IPR 2024-01312. [cited by applicant]
Office Action in U.S. Appl. No. 17/506,849 dated Sep. 6, 2024. [cited by applicant]
Full Prescribing Information of Levulan Kerastick, Mar. 2010. [cited by applicant]
Gold M. H. (Sep. 2008), “Therapeutic and Aesthetic Uses of Photodynamic Therapy Part two of a five-part series: Lasers and Light Treatments for Acne Vulgaris Promising Therapies”, The Journal of Clinical and Aesthetic D… [cited by applicant]
Infringement Claim Chart for U.S. Pat. No. 11,697,028 filed Jun. 25, 2024 in [cited by applicant]
Notice of Reasons for Refusal on JP 2023-146114 Dtd Aug. 13, 2024 (15 pages) (with English Translation). [cited by applicant]
Pariser, David M. et al., Randomized Vehicle-Controlled Study of short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp, American Society for Dermatologic Surgery, Inc.… [cited by applicant]
Patent Owner's Preliminary Response filed Aug. 22, 2024 in IPR 2024-00874. [cited by applicant]
Petition for Inter Partes Review of U.S. Pat. No. 11,697,028 filed Apr. 30, 2024 (IPR 2024-00874). [cited by applicant]
Petition for Inter Partes Review of U.S. Pat. No. 11,697,028 filed Aug. 21, 2024 (IPR 2024-01312). [cited by applicant]
Schmieder, G. et al., A Multicenter, Randomized, Vehicle-Controlled Phase 2 Study of Blue Light Photodynamic Therapy With Aminolevulinic Acid HCI 20% Topical Solution for the Treatment of Actinic Keratoses on the Upper … [cited by applicant]
Specimen for Beautylight, United States Trademark Serial No. 78214595, MDE Medizintechnik GmbH, Specimen submitted May 29, 2007. [cited by applicant]
Johanna T. H. M. van den Akker et al., “Effect of elevating the skin temperature during topical ALA application on in vitro ALA penetration through mouse skin and in vivo PpIX production in human skin” Photochem. Photob… [cited by applicant]
U.S. Appl. No. 17/854,066, filed Jun. 30, 2022, Willey, Andrea. [cited by applicant]
U.S. Appl. No. 17/876,224, filed Jul. 28, 2022, Lundahl, Scott et al. [cited by applicant]
U.S. Appl. No. 17/942,353, filed Sep. 12, 2022, Boyajian, Thomas et al. [cited by applicant]
Maisch et al., “Fluorescent Induction of Protoporphyrin IX by a New 5-Aminolevulinic Acid Nanoemulsion Used for Photodynamic Therapy in a Full-Thickness ex vivo Skin Model,” Experimental Dermatology, 19, © 2009, e302-e3… [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/487,698 Dtd Oct. 4, 2022, 6 pages. [cited by applicant]
USPTO Office Action in U.S. Appl. No. 17/876,224 Dtd Sep. 27, 2022, 20 pages. [cited by applicant]
Office Action in Japanese Application No. 2019-555822 mailed Nov. 1, 2022 and English translation thereof, 11 pages. [cited by applicant]
Touma, Yaar, Whitehead, Konnikov and Gilchrest, A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage, Arch Dermatol. Jan. 2004; 140(1): 33-40. [cited by applicant]
Ang et al., “Photodynamic Therapy and Pain: A Systematic Review,” Photodiagnosis and Photodynamic Therapy 19 (Jul. 2017) 308-344. [cited by applicant]
Kim et al. “In vivo skin absorption dynamics of topically applied pharmaceuticals monitored by fiber-optic diffuse reflectance spectroscopy,” Spectrochimica Acta Part A 66, Mar. 2007, 768-772. [cited by applicant]
Mordon S, A Commentary on the Role of Skin Temperature on the Effectiveness of ALA-PDT in Dermatology, Photodiagnosis and Photodynamic Therapy (Accepted Aug. 2014). [cited by applicant]
Nishimura et al., “Iontophoretic Photosensitization of the Skin Re-evaluated by Colorimetric Imaging in Senile Patients,” Bioimages 19, Jan. 2011, 1-6. [cited by applicant]
Warren et al., “Pain Associated with Aminolevulinic Acid-Photodynamic Therapy of Skin Disease,” J Am Acad Dermatol., Dec. 2009 61(6): 1033-1043. [cited by applicant]
Willey et al., “Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A Pilot Study” Dermatol Surg; 40:1094-1102, Oct. 2014. [cited by applicant]
Ye et al. “Evaluation of Hydrogel Suppositories for Delivery of 5-Aminolevulinic Acid and Hematoporphyrin Monomethyl Ether to Rectal Tumors,” Molecules, Oct. 2016, 21, 1347, 1-12. [cited by applicant]
Champeau et al. “Photodynamic therapy for skin cancer: How to enhance drug penetration?”, Journal of Photochemistry and Photobiology B: Biology, vol. 197, Jul. 2, 2019. [cited by applicant]
Affidavit of Duncan Hall, Aug. 10, 2021. [cited by applicant]
Agostinis et al. Photodynamic therapy of cancer: an update. CA: A Cancer Journal for Clinicians. May 2011; 61(4):250-2. [cited by applicant]
Aktilite CL128 Operators Manual with Metvixia, Revised 2008. [cited by applicant]
Ameluz, Prescribing Information (2016). [cited by applicant]
Australian Examination Report, Application No. 2020267186, Nov. 19, 2021,6 pages. [cited by applicant]
Australian Examination Report, Application No. 2020267186, Feb. 3, 2022, 4 pages. [cited by applicant]
Australian Examination Report, Application No. 2021107564, Apr. 4, 2022, 4 pages. [cited by applicant]
Australian Office Action, Application No. 2019200152, Nov. 11, 2019, 9 pages. [cited by applicant]
Berardesca E, Vignoli GP, Fideli D, Maibach H. Effect of occlusive dressings on the stratum corneum water holding capacity. The American Journal of the Medical Sciences. Jul. 1992;304(1):25-28. [cited by applicant]
Bissonnette R. Photodynamic therapy. In: Gold M.H., editor. Photodynamic Therapy in Dermatology. Springer Science and Business Media, LLC; New York, NY, USA: 2011. pp. 221-229. [cited by applicant]
Blu-U, Operating Manual (2006). [cited by applicant]
Braathen, Lasse R., et al. “Guidelines on the Use of Photodynamic Therapy for Nonmelanoma Skin Cancer: an International Consensus.” Journal of the American Academy of Dermatology 56.1, Jan. 2007, pp. 125-143. [cited by applicant]
Britannica, The Editors of Encyclopaedia, “Gel: Physics and Chemistry”, 4 pages, Jul. 20, 1998, and “Gel: Additional Information”, 1 page, Available on line at: https://www.britannica.com/science/gel and https://www.bri… [cited by applicant]
Calderhead RG. Light-emitting diode phototherapy in dermatological practice in lasers in dermatology and medicine. Lasers in Dermatology and Medicine. Aug. 2011:231-265. [cited by applicant]
CV of Dr. Howard Rogers MD, PHD. [cited by applicant]
Daniel Barolet et al., Radiant Near Infrared Light Emitting Diode Exposure as Skin Preparation to Enhance Photodynamic Therapy Inflammatory Type Acne Treatment Outcome, Lasers in Surgery and Medicine vol. 42, No. 2, Feb… [cited by applicant]
Declaration of Dr. Howard Rogers MD, PHD, Oct. 19, 2021. [cited by applicant]
Dragieva, G. et al., “A Randomized Controlled Clinical Trial of Topical Photodynamic Therapy with Methyl Aminolaevulinate in the Treatment of Actinic Keratoses in Transplant Recipients.” British Journal of Dermatology 1… [cited by applicant]
DUSA Levulan Press Release, Dec. 6, 1999. [cited by applicant]
European Medicines Agency CHMP Assessment Report (excerpts), Oct. 20, 2011. [cited by applicant]
European Office Action, Application No. 16787667.1, Sep. 24, 2019, 5 pages. [cited by applicant]
Extended European Search Report, Application No. 18835929.3, Mar. 12, 2021, 10 pages. [cited by applicant]
Extended European Search Report, Application No. 20214586.8, Jun. 2, 2021, 8 pages. [cited by applicant]
Fauteck Europe PMC Website Database Listing, Oct. 25, 2007. [cited by applicant]
Fauteck JD, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses,… [cited by applicant]
Fehr et al., Photodynamic Therapy of Vulvar and Vaginal Condyloma and Intraepithelial Neoplasia Using Topically Applied 5-Aminolevulinic Acid, Lasers in Surgery and Medicine, 2002, 30:273-279, 7 pages. [cited by applicant]
Fehr et al., Selective Photosensitizer Distribution in Vulvar Condyloma Acuminatum After Topical Application of 5-Aminolevulinic Acid, Am. J. Obstet. Gynecol., vol. 174(3), Mar. 1996, pp. 951-957. [cited by applicant]
GLAD.com.au: “GLAD History”, 2012, [online] URL: http://www.glad.com.au/about-glad/glad-history/, retrieved online Nov. 8, 2019. [cited by applicant]
Harris DR. Percutaneous absorption and the surface area of occluded skin: a scanning electron microscopic study. British Journal of Dermatology. 1974; 91(27-32). [cited by applicant]
Hongcharu W., Taylor C., Chang, Y., Aghasi, D., Suthamjariya, K., Anderson, R. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. Aug. 2000;115(2):183-92. [cited by applicant]
Hurlimann et al., Photodynamic Therapy of Superficial Basal Cell Carcinomas Using Topical 5-Aminolevulinic Acid in a Nanocolloid Lotion, Pharmacology and Treatment, Dermatology 197, 1998, pp. 248-254. [cited by applicant]
International Patent Reviews, LLC review of U.S. Pat. No. 10,357,567 dated Jul. 26, 2021. [cited by applicant]
International Preliminary Report on Patentability, PCT/US2016/056572, Apr. 26, 2018, 9 pages. [cited by applicant]
International Preliminary Report on Patentability, PCT/US2018/027070, Oct. 24, 2019, 10 pages. [cited by applicant]
International Search Report and Written Opinion International Application No. PCT/US2018/027070, Oct. 16, 2018, 18 pages. [cited by applicant]
International Search Report from PCT/US2018/042505, issued Oct. 2, 2018. [cited by applicant]
Japanese Office Action and English translation, Application No. 2019-555822, Jan. 11, 2022, 13 pages. [cited by applicant]
Japanese Office Action and English Translation, Application No. JP 2020-503004, Dated Aug. 2, 2022, 6 pages. [cited by applicant]
Jeffes E., Mccullough J., Weinstein G., Fergin P., Nelson J., Shull T., Simpson K., Bukaty L., Hoffman W., Fong N. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study… [cited by applicant]
Johanna T.H.M. Van Den Akker et al., Effect of Elevating the Skin Temperature During Topical ALA Application on in vitro ALA penetration Through Mouse Skin and in vivo PpIX production in Human Skin, Photochemical and Ph… [cited by applicant]
Kurwa, Habib A., et al., “A Randomized Paired Comparison of Photodynamic Therapy and Topical 5-Fluorouracil in the Treatment of Actinic Keratoses.” Journal of the American Academy of Dermatology 41.3, Sep. 1999, pp. 414… [cited by applicant]
Letter to UVBiotek, LLC dated Jul. 28, 2017 Re: K170187, Trade/Device Name: Photodynamic Therapy Device, available at https://www.accessdata.fda.gov/cdrh_docs/pdf17/K170187.pdf (accessed Apr. 30, 2020). [cited by applicant]
Levulan, Label (2002). [cited by applicant]
Levulan, Label (2009). [cited by applicant]
Maccormack, Mollie A., “Photodynamic Therapy in Dermatology: An Update on Applications and Outcomes.” Seminars in Cutaneous Medicine and Surgery. vol. 27, No. 1, WB Saunders, Mar. 2008, pp. 52-62. [cited by applicant]
Maisch et al., Fluorescence Induction of Protoporphyrin IX by a New 5-Aminolevulinic Acid Nanoemulsion Used for Photodynamic Therapy in a Full-Thickness ex vivo Skin Model, Experimental Dermatology, 19, 2009, pp. e302-e… [cited by applicant]
McLaren G. Photodynamic therapy. In: Pfenninger and Fowler's procedures for primary care. Third Ed. Mosby Elsevier; Philadelphia, PA: 2011. pp. 397-400. [cited by applicant]
News article entitled DUSA Pharmaceuticals To Pay U.S. $20.75 Million To Settle False Claims Act Allegations Relating To Promotion Of Unsupported Drug Administration Process, Aug. 24, 2020. [cited by applicant]
Notice of Allowance, U.S. Appl. No. 15/487,991, Jan. 15, 2020, 11 pages. [cited by applicant]
Notice of Allowance, U.S. Appl. No. 15/487,991, Oct. 2, 2019, 16 pages. [cited by applicant]
Notice of Allowance, U.S. Appl. No. 17/487,698, Apr. 29, 2022, 11 pages. [cited by applicant]
Nucci et al., Treatment of Anogenital Condylomata Acuminata with Topical Photodynamic Therapy: Report of 14 Cases and Review, International Journal of Infectious Diseases, 14S, 2010, pp. e280-e282. [cited by applicant]
Ozog, David M., et al., “Photodynamic Therapy: A Clinical Consensus Guide.” Dermatologic Surgery 42.7, Jul. 2016, pp. 804-827. [cited by applicant]
Palm M., Goldman PM. Aminolevulinic acid: actinic keratosis and photorejuvenation. In: Gold M.H., editor. Photodynamic Therapy in Dermatology. Springer Science and Business Media, LLC. Nov. 2011:5-30. [cited by applicant]
Partial International Search, Annex to Form PCT/ISA/206, International Application No. PCT/US2018/027070, Jul. 19, 2018, 10 pages. [cited by applicant]
Petition for Inter Partes Review Under 35 U.S.C. 312, Oct. 19, 2021. [cited by applicant]
Petras Juzenas et al., Uptake of Topically Applied 5-Aminolevulinic Acid and Production of Protoporphyrin IX in Normal Mouse Skin: Dependence on Skin Temperature, Photochemistry and photobiology, vol. 69, No. 4, Apr. 1,… [cited by applicant]
Reinhold et al., A Randomized, Double-Blind, Phase III, Multicentre Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) vs. Placebo in the Field-Directed Treatment of Mild-to-Moderate Actinic Keratosis wit… [cited by applicant]
Rick K, Sroka R, Stepp H, Kriegmair M, Huber RM, Jacob K, Baumgartner R. Pharmacokinetics of 5-aminolevulinic acidinduced protoporphyrin IX in skin and blood. J Photochem Photobiol B. Oct. 1997;40(3):313-9. [cited by applicant]
Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad … [cited by applicant]
Sotiriou E, Apalla Z, Maliamani F, Zaparas N, Panagiotidou D, Ioannides D. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the… [cited by applicant]
Sotiriou Pubmed Website Database Listing, Sep. 23, 2009. [cited by applicant]
Third Party Submission filed in U.S. Appl. No. 17/109,311, Jun. 21, 2021, 21 pages. [cited by applicant]
USPTO Advisory Action, U.S. Appl. No. 15/487,991, May 15, 2018, 5 pages. [cited by applicant]
USPTO Interview Summary, U.S. Appl. No. 15/487,991, Sep. 22, 2017, 4 pages. [cited by applicant]
USPTO Non-Final Office Action, U.S. Appl. No. 16/631,205, Mar. 3, 2022, 31 pages. [cited by applicant]
USPTO Notice of Allowance, U.S. Appl. No. 15/292,731, Nov. 14, 2019, 12 pages. [cited by applicant]
USPTO Notice of Allowance, U.S. Appl. No. 16/438,702, Mar. 22, 2021, 14 pages. [cited by applicant]
USPTO Notice of Allowance, U.S. Appl. No. 16/438,702, May 20, 2021, 10 pages. [cited by applicant]
USPTO Notice of Allowance, U.S. Appl. No. 17/009,871, Jul. 22, 2021, 14 pages. [cited by applicant]
USPTO Notice of Allowance, U.S. Appl. No. 17/109,311, Aug. 10, 2021, 14 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 15/487,991, Jul. 31, 2018, 20 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 15/487,991, Apr. 9, 2019, 27 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 15/487,991, Jun. 12, 2017, 22 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 15/487,991, Feb. 6, 2018, 19 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 16/438,702, Oct. 13, 2020, 17 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 16/791,004, Oct. 25, 2021, 26 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 16/808,631, Jan. 21, 2022, 28 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 17/009,871, Dec. 2, 2020, 15 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 17/109,311, Jul. 20, 2021, 17 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 17/487,698, Dec. 17, 2021, 21 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 17/009,871, Mar. 23, 2021, 9 pages. [cited by applicant]
USPTO Office Action, U.S. Appl. No. 17/109,311, Mar. 2, 2021, 16 pages. [cited by applicant]
Wachowska et al., Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of cancer. Molecules. May 2011; 16(5): 4140-4164. [cited by applicant]
Webpage printout, Hill Laboratories Company, “Aklarus Phototherapy Treatment System with Red, Blue and Infrared Wavelengths by Hill Therapeutics,” available at https://hilllabs.com/therapeutics/Aklarus-Photo-Therapy-Sys… [cited by applicant]
Willey A, Anderson RR, Sakamoto FH. Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities. Dermatologic Surgery. Oct. 2014;40(10):1094-1102. [cited by applicant]
Willey et al., American Society for Laser Medicine and Surgery Abstracts, #147, Ultra Fast Thermal PDT for Facial AKs: Proof of Concept Study, Mar. 2017, 2 pages. [cited by applicant]
Willey Pubmed Website Database Listing, Oct. 2014. [cited by applicant]
Wolf, Peter, et al., “Topical Photodynamic Therapy With Endogenous Porphyrins After Application of 5-Aminolevulinic Acid: An Alternative Treatment Modality for Solar Keratoses, Superficial Squamous Cell Carcinomas, and … [cited by applicant]
Zhang et al., “Topical 5-Aminolevulinic Photodynamic Therapy with Red Light vs Intense Pulsed Light for the Treatment of Acne Vulgaris _ A Spilit [sic] Face, Randomized, Prospective Study,” Dermato-Endocrinology, 2018, … [cited by applicant]
“About Actinic Keratosis (Keratoses)”; SOMA Skin & Laser; https://somalaser.com/skin-conditions/actinic-keratosis/; accessed Nov. 21, 2024; 2 pages. [cited by applicant]
“BLU-U - Blue Light for Acne and Actinic Keratosis”; SOMA Skin & Laser; https://somalaser.com/blu- for-acne; Nov. 21, 2024; 2 pages. [cited by applicant]
“Exhibit 10C: Technical Domestic Industry Claim Chart for U.S. Pat. No. 11,697,028 (“028 Patent”)—Sun Pharmaceutical Industries, Inc.'s BLU-U Blue Light Photodynamic Therapy Illuminator—Model 4170E (“Blu-U 4170E”) devic… [cited by applicant]
“How Levulan Kerastick BLU-U Works”; How It Works—Levulan Kerastick (aminolevulinic acid Hci) Blu-U; https://www.levulanhcp.com/how-it-works; accessed Nov. 21, 2024; 4 pages. [cited by applicant]
“How much space does a BLU-U require?”; Levulan Kerastick (aminolevulinic acid HCI) for Topical Solution, 20%; https://www.mydrugrep.com/mobile-campaigns/Levulan_V13a_01a/space_requirements.html; accessed Nov. 21, 2024;… [cited by applicant]
“How to Use Levulan Kerastick—BLU-U”; How To Use - Levulan Kerastick (aminolevulinic acid HCI) Blu-U; https://www.levulanhcp.com/how-to-use; accessed on Nov. 25, 2024; 6 pages. [cited by applicant]
“Michael Ehrenreich, Md, Faad, Dermatologist and Medical Director, SOMA Skin & Laser, Millburn, NJ”; https://somolaser.com/dr-michael-ehrenreich-md-millburn-dermatologist/; accessed Nov. 21, 2024; 3 pages. [cited by applicant]
“Photodynamic Therapy for Acne”; SOMA Skin & Laser; https://somalaser.com/photodynamic-therapy/; accessed Nov. 21, 2024; 1 page. [cited by applicant]
“Photodynamic Therapy for Actinic Keratoses and Skin Cancer”; SOMA Skin & Laser; https://somalaser.com/photodynamic-therapy-for-actinic-keratoses-and-skin-cancer/; accessed Nov. 21, 2024; 2 pages. [cited by applicant]
“Photodynamic Therapy for Skin Conditions”; SOMA Skin & Laser; https://www.somalaser.com/photodynamic-therapy-for-skin-conditions/; accessed Nov. 21, 2024; 4 pages. [cited by applicant]
“Photodynamic Therapy”; Photodynamic Therapy (PDT) - Dr. Heather Roberts; https://www.drheatherroberts.com/procedures-and-treatments/photodynamic-therapy-pdt-for-skin-cancer/; accessed Nov. 21, 2024; 3 pages. [cited by applicant]
“Proven Results for Levulan Kerastick (aminolevulinic acid HCI) Blu-U”; https://www.levulanhcp.com/efficacy#isi-homepage-levulan-hcp; accessed Nov. 25, 2024; 4 pages. [cited by applicant]
“Proximate”; Merriam Webster; https://www.merriam-webster.com/dictionary/proximate; accessed Oct. 22, 2024; 1 page. [cited by applicant]
“Recess”; Merriam-Webster's Collegiate Dictionary, Eleventh Edition; Meriam-Webster, Incorporated, Springfield, Massachusetts; 2005; p. 1038. [cited by applicant]
“Recess”; Merriam-Webster's Online Dictionary; https://www.merriam-webster.com/dictionary/recess; accessed on Oct. 17, 2024; 11 pages. [cited by applicant]
“Recess”; Oxford English Dictionary; Oxford University Press; 2024; 12 pages. [cited by applicant]
“Recess”; The American Heritage Dictionary; https://ahdictionary.com/word/search.html?q=recess; as accessed on Oct. 17, 2024; 3 pages. [cited by applicant]
“Strike AKs with Confidence”; Levulan Kerastick (aminolevulinic acid HCI) Blu-U—HCP Home Page; https://www.levulanhcp.com/; accessed on Nov. 25, 2024; 4 pages. [cited by applicant]
“Treatment Landscape—Levulan Kerastick (aminolevulinic acid HCI) Blu-U”; https://www.levulanhcp.com/treatment-landscape; accessed Nov. 21, 2024; 5 pages. [cited by applicant]
“Treat What Happened Yesterday, Today—Levulan Kerastick BLU-U”; Jan. 2021; 16 pages. [cited by applicant]
Allison, Ron R. et al.; “The future of photodynamic therapy in oncology”; Future Oncol, vol. 2, No. 1; Feb. 2006; pp. 53-71. [cited by applicant]
Amended Verified Complaint of Complainant Sun Pharmaceutical Industries, Inc., U.S. International Trade Commission Investigation 337-TA-1411, dated Oct. 29, 2024, 56 pages. [cited by applicant]
Avci, Pinar et al.; “Low-level laser (light) therapy (LLT) in skin: stimulating, healing, restoring”; Seminars in Cutaneous Medicine and Surgery, vol. 32, No. 1; Mar. 2013; pp. 41-52. [cited by applicant]
Barolet, Daniel; “Light-Emitting Diodes (LEDs) in Dermatology”; Seminars in Cutaneous Medicine and Surgery, vol. 27, No. 4; Dec. 2008; pp. 227-238. [cited by applicant]
Bourget, C. Michael; “An Introduction to Light-emitting Diodes”; HortScience, vol. 43, No. 7; Dec. 2008; pp. 1944-1946. [cited by applicant]